An immunocapture device that specifically captures bladder cancer cells from urine for analysis.

About

BACKGROUND Bladder cancer is on average the 9th most common of all cancers (the chance of developing bladder cancer is 1 in 27 for men and 1 in 89 for women), and the most expensive to treat from diagnosis to death because of its particularly high recurrence rate (

Key Benefits

• Non-invasive • No pre-processing of urine sample required • Significant improvement over current cytology approaches

Applications

This technology is relevant for the biomedical point of care diagnostic market.

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations